Market Overview

UPDATE: Morgan Stanley Initiates NPS Pharmaceuticals at Overweight on Portfolio Quality

Related NPSP
Bank Of America Q3 Small & Mid-Cap Biotech Preview
Benzinga's Weekend M&A Chatter

Morgan Stanley initiated coverage on NPS Pharmaceuticals (NASDAQ: NPSP) with an Overweight rating and a $17 price target

Morgan Stanley commented, "NPS has two novel, late stage assets that we believe have key characteristics that to us indicate a high chance of commercial success despite the increasingly difficult reimbursement environment: a) strong efficacy and safety with a good disease impact, b) target diseases with a high unmet need and high acuity, and c) a competitive/unique drug profile. We believe the Street undervalues these novel assets, removing the long term leverage from this focused, orphan model."

NPS Pharmaceuticals closed at $9.52 on Wednesday.

Latest Ratings for NPSP

DateFirmActionFromTo
Sep 2014FBR CapitalMaintainsOutperform
Aug 2014JefferiesMaintainsHold
May 2014Janney CapitalInitiates Coverage onBuy

View More Analyst Ratings for NPSP
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (NPSP)

Around the Web, We're Loving...

Get Benzinga's Newsletters